EMA seeks executive director

Andreas Pott will be acting executive director until position is filled

The European Medicines Agency (EMA) is seeking a new executive director. Its current head, Thomas Lönngren, is leaving the post on 31 December, following the end of his second five-year mandate.

While EMA searches for a permanent replacement, its current head of administration, Andreas Pott, will serve as acting executive director.

University of Hamburg graduate, Pott has been the agency’s administration chief since 2000, having previously worked for the European Parliament and the EU’s translation service.

Swede Lönngren is a former deputy director-general of the Swedish Medical Products Agency (MPA).

You may also like

Manufacturing

Streamlining bioconjugation for next-generation ADC development

Abzena’s proprietary ThioBridge™ technology delivers precision, scalability, and enhanced stability for antibody-drug conjugates
Manufacturing

Frontline innovation: dispatches from the show floor at CPHI Frankfurt (part I)

Discover how emerging technologies and expert insights are shaping the future of pharma manufacturing
You need to be a subscriber to read this article.
Click here to find out more.
Analysis

A pharmacodynamic analysis platform for targeted protein degrader drugs

Targeted protein degraders (TPDs) are an emerging class of therapeutics that harness a cell’s built-in waste removal process to eliminate disease-causing proteins
Manufacturing

Thermo Fisher Scientific highlights its new accelerator drug development solutions at CPHI Frankfurt 2025

The company has also announced a collaboration with OpenAI as well as a new digital toolbox, OSDPredict, which combines AI and machine learning models to predict formulation behaviour in small-molecule development
Manufacturing

Indena showcases expanded capabilities, innovative APIs and ADC partnership at CPHI 2025

Indena, a global leader in plant-derived active pharmaceutical ingredients (APIs), will present its latest technological and manufacturing advances at CPHI 2025 (Frankfurt, 28–30 October)
Manufacturing

SGD Pharma presents new innovations at CPHI Frankfurt 2025

SGD Pharma, a global leader in pharmaceutical glass primary packaging solutions, will showcase its enhanced portfolio of products and services at booth 8.0H24 during CPHI, taking place in Frankfurt, Germany, from 28–30 October
Finance

Cambrex unveils $120m investment to expand API manufacturing and strengthen US drug supply resilience

Cambrex's continued investments underscore its commitment to adding capabilities and increasing capacity to meet the evolving needs and growing demand of the pharmaceutical industry.
Subscribe now